Table 2.
Association between gene polymorphisms in NER pathway and response to chemotherapy
| Gene | Total | % | CR+PR | % | SD+PD | % | OR (95% CI) | P value |
|---|---|---|---|---|---|---|---|---|
| ERCC1 rs11615 | ||||||||
| TT | 162 | 39.5 | 101 | 37.5 | 61 | 43.3 | 1.0 (Ref.) | - |
| TC | 187 | 45.6 | 124 | 46.1 | 63 | 44.7 | 1.19 (0.75-1.89) | 0.44 |
| CC | 61 | 14.9 | 44 | 16.4 | 17 | 12.1 | 1.56 (0.79-3.18) | 0.17 |
| ERCC1 rs3212986 | ||||||||
| GG | 187 | 45.6 | 104 | 38.7 | 83 | 58.9 | 1.0 (Ref.) | - |
| GT | 169 | 41.2 | 117 | 43.5 | 52 | 36.9 | 1.80 (1.14-2.85) | 0.008 |
| TT | 54 | 13.2 | 48 | 17.8 | 6 | 4.3 | 6.38 (2.54-19.03) | <0.05 |
| ERCC2 rs13181 | ||||||||
| AA | 158 | 38.5 | 89 | 33.1 | 69 | 48.9 | 1.0 (Ref.) | - |
| AC | 175 | 42.7 | 123 | 45.7 | 52 | 36.9 | 1.83 (1.14-2.96) | 0.01 |
| CC | 77 | 18.8 | 57 | 21.2 | 20 | 14.2 | 2.21 (1.17-4.25) | 0.01 |
| ERCC2 rs1799793 | ||||||||
| GG | 174 | 42.4 | 108 | 40.1 | 66 | 46.8 | 1.0 (Ref.) | - |
| GA | 188 | 45.9 | 123 | 45.7 | 65 | 46.1 | 1.16 (0.74-1.82) | 0.51 |
| AA | 48 | 11.7 | 37 | 13.8 | 11 | 7.8 | 2.06 (0.94-4.77) | 0.06 |
| ERCC5 rs17655 | ||||||||
| CC | 183 | 44.6 | 104 | 38.7 | 79 | 56.0 | 1.0 (Ref.) | - |
| CG | 174 | 42.4 | 116 | 43.1 | 58 | 41.1 | 1.52 (0.97-2.39) | 0.06 |
| GG | 73 | 17.8 | 49 | 18.2 | 24 | 17.0 | 1.55 (0.85-2.88) | 0.13 |
| XPA rs1800975 | ||||||||
| AA | 194 | 47.3 | 120 | 44.6 | 74 | 52.5 | 1.0 (Ref.) | - |
| AG | 165 | 40.2 | 113 | 42.0 | 52 | 36.9 | 1.34 (0.85-2.13) | 0.19 |
| GG | 51 | 12.4 | 36 | 13.4 | 15 | 10.6 | 1.48 (0.73-3.11) | 0.25 |
| XPC rs2228001 | ||||||||
| AA | 215 | 52.4 | 131 | 48.7 | 84 | 59.6 | 1.0 (Ref.) | - |
| AC | 128 | 31.2 | 90 | 33.5 | 38 | 27.0 | 1.52 (0.93-2.50) | 0.08 |
| CC | 67 | 16.3 | 48 | 17.8 | 19 | 13.5 | 1.62 (0.86-3.12) | 0.11 |